Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Update

Atossa Therapeutics, Inc. (NASDAQ:ATOS) was the recipient of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 11,600,000 shares, a decrease of 6.8% from the November 15th total of 12,450,000 shares. Based on an average daily volume of 628,500 shares, the days-to-cover ratio is currently 18.5 days.

Analyst Ratings Changes

A number of brokerages recently weighed in on ATOS. Ascendiant Capital Markets lifted their price objective on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Atossa Therapeutics in a research note on Thursday, December 12th. Finally, StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th.

Hedge Funds Weigh In On Atossa Therapeutics

Institutional investors have recently modified their holdings of the company. Intech Investment Management LLC purchased a new position in Atossa Therapeutics during the third quarter worth approximately $29,000. XTX Topco Ltd purchased a new stake in shares of Atossa Therapeutics in the second quarter worth about $29,000. Cetera Advisors LLC acquired a new position in shares of Atossa Therapeutics during the first quarter worth $72,000. SG Americas Securities LLC increased its stake in Atossa Therapeutics by 254.3% during the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after buying an additional 30,037 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Atossa Therapeutics in the third quarter worth about $75,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Price Performance

ATOS traded down $0.02 during trading on Tuesday, reaching $1.05. 137,073 shares of the stock were exchanged, compared to its average volume of 1,057,449. Atossa Therapeutics has a 1 year low of $0.70 and a 1 year high of $2.31. The company has a market capitalization of $132.09 million, a price-to-earnings ratio of -4.86 and a beta of 1.21. The business’s 50 day moving average price is $1.35 and its two-hundred day moving average price is $1.33.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.